BackUroGen Pharma Overview
UroGen Pharma Ltd

UroGen Pharma Target Price

Analysts' average 12-month price target for UroGen Pharma is $54.

Get informed when a big investor buys or sells

+ Follow

Share Price

$42.76

Average Target Price

$54.1726.7% upside

6 analysts in the last 4 months

High: $75 | Low: $42

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-10JefferiesAmin Makarem$5631% upsideOpen
2026-08-06GuggenheimMichael Schmidt$5835.6% upsideOpen
2026-08-06H.C. Wainwright$7575.4% upsideOpen
2026-07-21Guggenheim$421.8% downsideOpen
2026-07-16OppenheimerLeland Gershell$5016.9% upsideOpen
2026-07-15Goldman Sachs$442.9% upsideOpen
2026-05-11H.C. WainwrightRaghuram Selvaraju$455.2% upsideOpen
2026-04-09JefferiesAmin Makarem$406.5% downsideOpen
2025-06-13Goldman SachsPaul Choi$1662.6% downsideOpen
2025-06-13OppenheimerLeland Gershell$3127.5% downsideOpen
2024-10-14EF HuttonJason Kolbert$2541.5% downsideOpen
2024-06-14Evercore ISIStephen Richardson$467.6% upsideOpen
2024-06-14OppenheimerLeland Gershell$406.5% downsideOpen
2024-06-14H.C. WainwrightRaghuram Selvaraju$6040.3% upsideOpen
2024-06-14Goldman SachsPaul Choi$2248.6% downsideOpen
2024-05-14OppenheimerLeland Gershell$3225.2% downsideOpen
2024-03-15OppenheimerLeland Gershell$3420.5% downsideOpen
2022-12-12H.C. Wainwright$2346.2% downsideOpen

UroGen Pharma (URGN) FAQ

UroGen Pharma (URGN) currently reports a target price of $54. Use the charts on this page to explore UroGen Pharma's target price history and peer comparisons.

Analysts' average 12-month price target for UroGen Pharma is $54, about 26.7% upside from the current share price of $42.76. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $54, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for UroGen Pharma, and consider following URGN for alerts when major investors trade the stock.

UroGen Pharma is classified in the Healthcare sector. On target price, it currently shows $54. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing URGN with unrelated industries.